Definitive Contract 75F40119C10040
- Not listed
- Pacific Biosciences of California, Inc., a small business biotechnology firm specializing in long-read DNA and RNA sequencing technologies, received a $726,318.04 firm fixed-price purchase order from the Food and Drug Administration on September 28, 2023. The award covers a Sequel IIE long-read DNA/RNA sequencer system and associated consumables to support the National Antimicrobial Resistance Monitoring System. The contract, designated as a total small business set-aside, includes performance...
- This contract award to Pacific Biosciences of California, Inc., a small business manufacturer, is for the provision of high-throughput, long-read DNA sequencing systems and associated consumables to the U.S. Food and Drug Administration (FDA). The $83,644 firm fixed-price purchase order has an ultimate completion date of October 14, 2015. Pacific Biosciences is the original equipment manufacturer for their proprietary single molecule, real-time (SMRT) sequencing technology, which is utilized...
- The Food and Drug Administration (FDA) awarded a firm-fixed-price service contract to Pacific Biosciences of California, Inc. for $314,960.99 to provide parts, labor, and preventative maintenance for a Sequel 2e long-read sequencer located in Berwyn Heights, MD. The service contract will cover annual inspections and priority repairs within three business days to maintain the sequencer and generate consistent, high-quality data to help the FDA resolve foodborne disease outbreaks. This award was...
- The Food and Drug Administration awarded a $47,897.16 delivery order to Pacific Biosciences of California, Inc. on March 30, 2026, for supplies and reagents supporting the PacBio Sequel IIe long-read DNA/RNA sequencer. This delivery order was issued under the FDA's existing Indefinite Delivery Indefinite Quantity (IDIQ) contract 75F40121D00007 with Pacific Biosciences, valued at $1 million and originally extending through March 2025. The work will be performed in Laurel, Maryland, with an...
- The U.S. Food and Drug Administration (FDA) has awarded a $39,657.00 firm fixed-price delivery order to Pacific Biosciences of California, Inc. (PacBio) under the company's existing $1 million Indefinite Delivery, Indefinite Quantity (IDIQ) contract with the agency. This delivery order is for the purchase of specific supplies and reagents to support the agency's use of PacBio's Sequel IIe long-read DNA/RNA sequencing platform. The award, made without a set-aside designation, is the latest task...
- The Department of Health and Human Services Food and Drug Administration awarded a $51,193.93 purchase order to Pacific Biosciences of California, Inc. for sequencing supplies. The firm fixed price contract runs from August 23, 2023 to February 19, 2024 and will be performed by Pacific Biosciences in West Menlo Park, California. The original solicitation sought sequencing supplies as described in Combined Synopsis Solicitation 75F40123Q-117934 to support the FDA's evaluation of new sequencing...
- This federal contract award is for the procurement of PacBio Sequel II and IIe system reagents and consumables by the Food and Drug Administration (FDA). The $15,713.10 firm-fixed price contract was awarded on July 23, 2024 to Pacific Biosciences of California, Inc., a leading manufacturer of high-throughput, long-read DNA sequencing platforms and associated products. The contract does not have a set-aside designation. Pacific Biosciences holds two relevant Indefinite Delivery Indefinite...
- The Department of Health and Human Services Food and Drug Administration awarded a $433,950.00 firm fixed price purchase order to Pacific Biosciences of California, Inc. to provide a DNA sequencer with accessories. The contract has no set-aside designation and was completed on August 29, 2019. Pacific Biosciences is a manufacturer of specialized scientific equipment, reagents, and services for DNA/RNA sequencing. They have fulfilled over $10 million in federal contracts, including with the...
- The Food and Drug Administration awarded a $22.9K firm fixed-price purchase order to Pacific Biosciences of California, Inc., a Menlo Park-based biotechnology manufacturer specializing in advanced DNA and RNA sequencing technologies. The award, designated as a total small business set-aside, was executed on July 27, 2021, for SMRT cell 8M trays and Sequel II sequencing kits—consumable products essential for next-generation sequencing operations. The procurement was completed ahead of the October...
- This federal contract award to Pacific Biosciences of California, Inc. (PacBio) provides for the delivery of a PacBio RS DNA sequencing system with a 12-month service contract. The $998,000.00 firm fixed price contract was awarded by the Food and Drug Administration (FDA), a civilian agency, without the use of a set-aside. PacBio is the original equipment manufacturer for the PacBio Sequel and Sequel II sequencing platforms, which are in high demand across federal agencies for genomic research...
The U.S. Food and Drug Administration awarded a $736,000 firm fixed-price definitive contract to Pacific Biosciences of California, Inc. for a real-time sequencer system with four one-year post-warranty maintenance option periods. The contract, awarded on September 3, 2019, with an ultimate completion date of December 11, 2024, is designated as a Total Small Business set-aside. Pacific Biosciences, a leading biotechnology company specializing in advanced DNA and RNA sequencing technologies, will deliver its specialized sequencing platform along with associated maintenance support services to support the FDA's scientific research and regulatory science capabilities. This contract award reflects the FDA's reliance on Pacific Biosciences' long-read sequencing systems for genomic research applications critical to the agency's mission. Pacific Biosciences has established itself as a key supplier across multiple federal agencies, including the USDA, NIH, CDC, and Department of Defense, providing not only sequencing instruments but also reagents, consumables, and technical support. The company maintains significant contract vehicles with federal agencies, including a $1 million Indefinite Delivery Indefinite Quantity agreement with the FDA itself, awarded in March 2021, which provides flexible procurement mechanisms for sequencing reagents and consumables beyond this specific equipment award.
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
Real Time Sequencer | FDA_19-223-SOL-1209653 | Department of Health and Human Services Food and Drug Administration | Pre-Solicitation 1/3 | 3/25/19, 10:44 AM | |
Real Time Sequencer | FDA_19-223-SOL-1209653 | Department of Health and Human Services Food and Drug Administration | Solicitation 2/3 | 4/10/19, 2:00 PM | |
Real Time Sequencer | FDA_19-223-SOL-1209653 | Department of Health and Human Services Food and Drug Administration Office of Acquisition and Grant Services | Award Notice 3/3 | 9/4/19, 8:56 AM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00004 | Exercise an Option | $50.0k | 11/3/23 | |
| P00003 | Exercise an Option | $50.0k | 11/2/22 | |
| P00002 | Exercise an Option | $50.0k | 11/3/21 | |
| P00001 | Exercise an Option | $50.0k | 10/22/20 | |
| Not listed | Not listed | $536.0k | 9/3/19 |